Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

134.70USD
22 Aug 2017
Change (% chg)

-- (--)
Prev Close
$134.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
5,548,547
52-wk High
$137.08
52-wk Low
$109.32

Latest Key Developments (Source: Significant Developments)

Cerecor Inc Q2 loss per share $0.14
Monday, 14 Aug 2017 08:02am EDT 

Aug 14 (Reuters) - Cerecor Inc :Cerecor Inc reports second quarter 2017 financial results.Q2 loss per share $0.14.Q2 revenue $200,000.In August 2017, co sold its world-wide rights of CERC-501 to Janssen in exchange for an initial payment of $25 million​.Under agreement, Janssen will assume ongoing clinical trials and be responsible for any new development or commercialization of CERC-501..Expect existing cash & cash equivalents & proceeds from Janssen sale, to fund operating expenditure requirements through at least 2018.  Full Article

BRIEF-Genmab CEO confident to close some tech deals this year
Thursday, 10 Aug 2017 01:03am EDT 

Repeats Wednesday's story without changes to text:IS IN PROGRESSING TALKS WITH SEVERAL COMPANIES ON NEW TECHNOLOGY COLLABORATIONS, CONFIDENT TO CLOSE SOME DEALS IN 2017, AND SOME IN 2018.DEALS ARE MORE COMPLICATED TO MAKE NOW THAN EARLIER AS GENMAB WANTS CO-OWNERSHIP OR THE OPTION OF CO-OWNERSHIP AND THAT IS NOT WHAT THE LARGE BIOTECH AND PHARMA COMPANIES LIKE TO HEAR.NEW DEALS ARE GOING TO BE MORE FAVOURABLE TOWARDS GENMAB IN THE FUTURE AS ITS DRUGS ARE WORKING WELL AND POTENTIAL PARTNERS ARE VERY EAGER TO GET ACCESS TO ITS TECHNOLOGIES.IS MOVING AGGRESSIVELY FORWARD TOGETHER WITH JANSSEN ON SUBCUTANEOUS FORMULATION OF DARATUMUMAB.IT IS INCREDIBLY IMPORTANT THAT GENMAB HAS REACHED AGREEMENT WITH REGULATORS ON HOW TO GET SUBCUTANEOUS FORMULATION OF DARATUMUMAB TO MARKET.STILL SEE LOT OF UNCERTAINTIES IN 2017, STILL NEED TO SEE PICK-UP IN DARZALEX SALES IN H2.  Full Article

Genmab CEO confident to close some tech deals this year
Wednesday, 9 Aug 2017 10:15am EDT 

Aug 9 (Reuters) - GENMAB'S CEO JAN VAN DE WINKEL SAYS IN TELEPHONE INTERVIEW WITH REUTERS::IS IN PROGRESSING TALKS WITH SEVERAL COMPANIES ON NEW TECHNOLOGY COLLABORATIONS, CONFIDENT TO CLOSE SOME DEALS IN 2017, AND SOME IN 2018.DEALS ARE MORE COMPLICATED TO MAKE NOW THAN EARLIER AS GENMAB WANTS CO-OWNERSHIP OR THE OPTION OF CO-OWNERSHIP AND THAT IS NOT WHAT THE LARGE BIOTECH AND PHARMA COMPANIES LIKE TO HEAR.NEW DEALS ARE GOING TO BE MORE FAVOURABLE TOWARDS GENMAB IN THE FUTURE AS ITS DRUGS ARE WORKING WELL AND POTENTIAL PARTNERS ARE VERY EAGER TO GET ACCESS TO ITS TECHNOLOGIES.IS MOVING AGGRESSIVELY FORWARD TOGETHER WITH JANSSEN ON SUBCUTANEOUS FORMULATION OF DARATUMUMAB.IT IS INCREDIBLY IMPORTANT THAT GENMAB HAS REACHED AGREEMENT WITH REGULATORS ON HOW TO GET SUBCUTANEOUS FORMULATION OF DARATUMUMAB TO MARKET.STILL SEE LOT OF UNCERTAINTIES IN 2017, STILL NEED TO SEE PICK-UP IN DARZALEX SALES IN H2.  Full Article

DePuy Synthes collaborates with Medical Enterprises Distribution to co-market ME1000
Monday, 7 Aug 2017 08:38am EDT 

Aug 7 (Reuters) - Johnson & Johnson :DePuy Synthes says exclusive agreement with Medical Enterprises Distribution to co-market ME1000 surgical impactor for use in Total Hip Arthroplasty.DePuy Synthes - is expected to begin co-marketing ME1000 with Medical Enterprises Distribution LLC within current quarter​.DePuy Synthes says is expected to begin co-marketing ME1000 with Medical Enterprises Distribution LLC within current quarter.DePuy Synthes - ME1000 is designed to replace handheld mallet used in Total Hip Arthroplasty.  Full Article

J&J says received subpoena in June from U.S. attorney's office
Thursday, 3 Aug 2017 05:32pm EDT 

Aug 3 (Reuters) - Johnson & Johnson -:J&J - in June 2017, co received a subpoena from the united states attorney's office for the district of Massachusetts‍​ - sec filing.J&J - June subpoena seeks information regarding practices related to sterilization of depuy synthes spinal implants at three hospitals in boston.J&J - June subpoena also seeks information regarding interactions of company employees with physicians at 3 boston hospitals.J&J - expects restructuring actions in medical devices segment will result eliminations of about 4 to 6 percent of segment’s global workforce over next 18 months‍​.J&J says about 2,100 positions have been eliminated of which 1,650 received separation payments since the restructuring announcement.  Full Article

Johnson & Johnson announces encouraging first-in-human clinical data for investigational HIV preventive vaccine
Monday, 24 Jul 2017 04:00am EDT 

July 24 (Reuters) - J&J :Johnson & Johnson announces encouraging first-in-human clinical data for investigational HIV preventive vaccine.Phase 1/2a approach study, HIV-1 antibody response observed in all healthy volunteers.Positive clinical, preclinical results inform selection of lead mosaic HIV vaccine regimen for further evaluation in phase 2b proof-of-concept study.J&J says should study move forward, Janssen and its global partners anticipate initiating this investigation in southern African countries in late 2017 or early 2018.  Full Article

EU Medicines Agency recommends approval J&J unit's Symtuza drug for HIV
Friday, 21 Jul 2017 07:26am EDT 

July 21 (Reuters) - EU Medicines Agency::EU Medicines Agency recommends approval of Johnson & Johnson unit Janssen-Cilag International N.V. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Symtuza) drug for HIV.  Full Article

Johnson & Johnson Q2 earnings per share $1.40
Tuesday, 18 Jul 2017 06:40am EDT 

July 18 (Reuters) - Johnson & Johnson ::Johnson & Johnson reports 2017 second-quarter results:.Q2 earnings per share $1.40.Q2 sales $18.8 billion versus I/B/E/S view $18.95 billion.Q2 earnings per share view $1.80 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $7.12 to $7.22.Q2 adjusted non-gaap earnings per share $1.83 excluding items.Sees FY 2017 sales $75.8 billion to $76.1 billion.J&J - ‍full-year adjusted EPS guidance increased to a range of $7.12 to $7.22​.J&J says worldwide consumer sales of $3.5 billion for Q2 2017 represented an increase of 1.7% versus prior year.J&J - ‍worldwide medical devices sales of $6.7 billion for Q2 2017 represented an increase of 4.9% versus prior year​.J&J says worldwide pharmaceutical sales of $8.6 billion for Q2 2017 represented a decrease of 0.2% versus prior year.J&J - excluding items, ‍on operational basis, Q2 worldwide sales increased 0.5%, domestic sales decreased 1.0% and international sales increased 2.0%​.FY 2017 earnings per share view $7.10 -- Thomson Reuters I/B/E/S.J&J qtrly worldwide invokana/invokamet sales $‍​295 million versus $284 million in Q1.J&J - qtrly worldwide velcade sales $ ‍​290 million versus $280 million in Q1 2017.FY 2017 revenue view $75.68 billion -- Thomson Reuters I/B/E/S.J&J - ‍second-quarter 2017 net earnings included after-tax intangible amortization expense of approximately $0.4 billion​.Q2 worldwide remicade sales $‍1,530​ million versus $1,672 million in Q1 2017.  Full Article

J&J sets quarterly cash dividend of $0.84 per share
Monday, 17 Jul 2017 10:33am EDT 

July 17 (Reuters) - J&J ::Sets quarterly cash dividend of $0.84 per share.  Full Article

Janssen announces FDA approval of Tremfya
Thursday, 13 Jul 2017 04:10pm EDT 

July 13 (Reuters) - Johnson & Johnson :Janssen announces U.S. FDA approval of Tremfya (guselkumab) for the treatment of moderate to severe plaque psoriasis.Janssen says Tremfya demonstrated superior results in skin clearance compared with Humira in head-to-head analyses at weeks 16, 24 and 48.Janssen- ‍seven out of ten patients receiving Tremfya achieved at least 90 percent improvement in skin clearance at week 16​.Janssen says applications seeking approval in European union, Japan and other countries are currently under review.  Full Article

Photo

Massive California verdict expands J&J's talc battlefield

NEW YORK A massive California verdict in a lawsuit alleging Johnson & Johnson's talc-based products cause cancer has opened a new front in the litigation, upending the company's hopes that the cases were only gaining traction in Missouri, legal experts said.